251 related articles for article (PubMed ID: 17431103)
1. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts.
Rosenthal EL; Kulbersh BD; King T; Chaudhuri TR; Zinn KR
Mol Cancer Ther; 2007 Apr; 6(4):1230-8. PubMed ID: 17431103
[TBL] [Abstract][Full Text] [Related]
2. Optical imaging predicts tumor response to anti-EGFR therapy.
Helman EE; Newman JR; Dean NR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2010 Jul; 10(2):166-71. PubMed ID: 20505368
[TBL] [Abstract][Full Text] [Related]
3. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence.
Rosenthal EL; Kulbersh BD; Duncan RD; Zhang W; Magnuson JS; Carroll WR; Zinn K
Laryngoscope; 2006 Sep; 116(9):1636-41. PubMed ID: 16954995
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model.
Gleysteen JP; Newman JR; Chhieng D; Frost A; Zinn KR; Rosenthal EL
Head Neck; 2008 Jun; 30(6):782-9. PubMed ID: 18228526
[TBL] [Abstract][Full Text] [Related]
5. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.
Day KE; Sweeny L; Kulbersh B; Zinn KR; Rosenthal EL
Mol Imaging Biol; 2013 Dec; 15(6):722-9. PubMed ID: 23715932
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts.
Kulbersh BD; Duncan RD; Magnuson JS; Skipper JB; Zinn K; Rosenthal EL
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):511-5. PubMed ID: 17520766
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma.
Knowles JA; Heath CH; Saini R; Umphrey H; Warram J; Hoyt K; Rosenthal EL
Arch Otolaryngol Head Neck Surg; 2012 Jul; 138(7):662-8. PubMed ID: 22801891
[TBL] [Abstract][Full Text] [Related]
8. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
9. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
10. Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts.
Withrow KP; Newman JR; Skipper JB; Gleysteen JP; Magnuson JS; Zinn K; Rosenthal EL
Technol Cancer Res Treat; 2008 Feb; 7(1):61-6. PubMed ID: 18198926
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
13. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
[TBL] [Abstract][Full Text] [Related]
14. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and preclinical investigation of
Shah SQ; Gul-E-Raana
Mol Biol Rep; 2019 Apr; 46(2):1675-1682. PubMed ID: 30680596
[TBL] [Abstract][Full Text] [Related]
16. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model.
Heath CH; Deep NL; Sweeny L; Zinn KR; Rosenthal EL
Ann Surg Oncol; 2012 Nov; 19(12):3879-87. PubMed ID: 22669455
[TBL] [Abstract][Full Text] [Related]
17. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
Li C; Iida M; Dunn EF; Wheeler DL
Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
20. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]